<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04149899</url>
  </required_header>
  <id_info>
    <org_study_id>WB007-001</org_study_id>
    <nct_id>NCT04149899</nct_id>
  </id_info>
  <brief_title>Safety and IOP-Lowering Effects of WB007</brief_title>
  <official_title>A Phase 1/2a Assessment of WB007 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Whitecap Biosciences, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Whitecap Biosciences, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and IOP-lowering effects of WB007 in adults with primary open-angle
      glaucoma or ocular hypertension in both eyes. This is a 2-part study. Part 1 will look at up
      to 3 formulations of WB007 ophthalmic solution following a single dose in one eye. Part 2
      will look at up to 2 formulations of WB007 (to be selected based on results from Part 1) in
      both eyes compared with timolol 0.5% for 14 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1 - Open-labelled, single dose, Dose escalation; Part 2 - Double-masked, randomized, parallel comparison</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part 1 - not masked; Part 2 - Double-masked - neither investigator, study staff nor study participant will be aware of treatment assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from Baseline in intraocular pressure (IOP) at Day 14</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>IOP measured by Goldmann applanation tonometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean IOP at Day 14</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>IOP measured by Goldmann applanation tonometry</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Glaucoma, Primary Open Angle</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Study Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WB007 Formulation 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WB007 Formulation 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WB007 Formulation 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Timolol maleate ophthalmic solution, 0.5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study Treatment 1 WB007</intervention_name>
    <description>Dosed for 14 days in both eyes</description>
    <arm_group_label>Study Treatment 1</arm_group_label>
    <other_name>WB007 Formulation 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study Treatment 2 WB007</intervention_name>
    <description>Dosed for 14 days in both eyes</description>
    <arm_group_label>Study Treatment 2</arm_group_label>
    <other_name>WB007 Formulation 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study Treatment 3 WB007</intervention_name>
    <description>Dosed for 14 days in both eyes</description>
    <arm_group_label>Study Treatment 3</arm_group_label>
    <other_name>WB007 Formulation 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol 0.5%</intervention_name>
    <description>Dosed for 14 days in both eyes</description>
    <arm_group_label>Timolol 0.5%</arm_group_label>
    <other_name>timolol maleate ophthalmic solution 0.5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ocular hypertension or primary open-angle glaucoma in each eye

        Exclusion Criteria:

          -  History of orthostatic hypotension

          -  Any active ocular disease

          -  Anticipated wearing of contact lenses during study

          -  Contraindication to pupil dilatation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wirta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Research Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JANIX</last_name>
    <phone>949-251-9800</phone>
    <email>sierra@janix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POAG</keyword>
  <keyword>OHT</keyword>
  <keyword>Primary open-angle glaucoma</keyword>
  <keyword>ocular hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

